HARP - מכפיל P/S Harpoon Tx

Automating antibody synthesis in robotic laboratories is accelerating drug development for Harpoon Therapeutics (HARP). Integration into the Merck structure secured trispecific antibody assets under FDA supervision. The scientific staff relies on autonomy and RSU packages. The price-to-sales multiple on the GURU.Markets chart demonstrates P/S dynamics, where 13.20 describes the current status of the metric.

The P/S ratio compares market capitalization to actual operating revenue, determining the extent of the premium paid for current business value growth rates. By analyzing price-to-sales dynamics, an investor assesses the valuation of Harpoon Therapeutics (HARP) through the lens of the TriTAC platform's uniqueness and the protection of R&D assets, which create a sustainable competitive advantage in the solid tumor therapy segment.